BioSpace News Archive

Neogen ® Corporation (NASDAQ: NEOG) announced today that it has released its innovative Veratox ® VIP assay for the detection of walnut, the third assay in Neogen’s Veratox VIP line of enhanced quantitative ELISA products.

Johnson & Johnson MedTech 1 today announced the completion of the acquisition 2 of Laminar, Inc., a privately-held medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib).

Monogram Orthopaedics Inc. will host a live stream product demonstration of features of its commercial robot on Thursday, December 14, 2023, at 11:00 a.m. Eastern Time.

Ausel Cancer Innovation, a clinical-stage healthcare company developing novel cancer diagnostic technology, has begun enrollment in its final study in the EU in patients with breast and lung cancers.

Procyrion, Inc. announced the enrollment of the first patients in the company’s IDE pivotal trial.

Cyclacel Pharmaceuticals, Inc. today announced that it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained compliance with Nasdaq Listing Rule 5250(c)(1).

Rafarma Pharmaceuticals (OTC: RAFA). The Company is pleased to announce that it has completed the restructuring, accounting and balance sheet procedures required to comply with GAAP auditing standards.

HUTCHMED Limited highlights that new clinical data from several ongoing studies with HUTCHMED investigational drug candidates fruquintinib, surufatinib and HMPL-295, which will be presented at the upcoming European Society for Medical Oncology Asia Congress, taking place on December 1-3, 2023 in Singapore, and the ESMO Immuno-Oncology Congress, taking place on December 6-8, 2023 in Geneva, Switzerland.

Innovent Biologics, Inc. announces the publication of updated clinical data of IBI351 monotherapy in non-small cell lung cancer and colorectal cancer at the European Society for Medical Oncology Asia Congress 2023, held during December 1-3 in Singapore.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”) today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO, and Narayan Prabhu, CFO of Reviva, will participate in The Benchmark Company’s Discovery One-on-One Investor Conference, taking place December 7, 2023 in New York, NY.